HER2CLIMB: A PIVOTAL TRIAL REPRESENTATIVE OF A HETEROGENEOUS POPULATION1-4



 Global    ✓ Randomized    ✓ Double-Blind    ✓ Controlled


Patients with unresectable locally advanced or metastatic HER2+ breast cancer who had received prior trastuzumab, pertuzumab, and T-DM1 separately or in combination, in the neoadjuvant, adjuvant, or metastatic setting were eligible to enroll.1

HER2CLIMB trial design: 612 patients were randomized (2:1) into the TUKYSA arm (n = 410; received TUKYSA + trastuzumab + capecitabine) or control arm (n = 202; received placebo + trastuzumab + capecitabine)

PRIMARY ENDPOINT1*


  • PFS (n = 480)

KEY SECONDARY ENDPOINTS1


  • OS (N = 612)
  • PFS in patients with brain metastases (n = 291)
  • Confirmed ORR for patients with measurable disease at baseline (n = 511)

  • Dosing was repeated every 21 days: TUKYSA (tucatinib), 300 mg orally, twice daily, or placebo, twice daily; trastuzumab, 6 mg/kg intravenously, once every 21 days with an initial dose of 8 mg/kg (subcutaneous dosing was also allowed); capecitabine, 1000 mg/m2 orally, twice daily, on Days 1-141
  • PFS (primary endpoint) was assessed in the first 480 randomized patients; secondary endpoints were assessed in the total population1
  • Patients were stratified according to whether brain metastases were present (yes or no), ECOG performance status score (0 or 1), and geographic region (United States, Canada, or rest of world)1

*Target enrollment for HER2CLIMB was increased twice to ensure there was adequate statistical power to assess the primary endpoint and, subsequently, a key secondary endpoint.2
Evaluated in accordance with RECIST, version 1.1, by means of BICR.1
BICR = blinded independent central review; ECOG = Eastern Cooperative Oncology Group; HER = human epidermal growth factor receptor; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; RECIST = Response Evaluation Criteria in Solid Tumors; T-DM1 = ado-trastuzumab emtansine.

Exploratory analyses

  • PFS in patients without brain metastases4
  • Disease control rate4*
  • Time to response3
  • Time to new brain lesions5

*Disease control rate is the percentage of patients with an evaluable scan post-baseline assessment who achieved a best response of CR, PR, or SD.6

CR = complete response; PR = partial response; SD = stable disease.

HER2CLIMB follow-up analysis

  • The HER2CLIMB protocol included a prespecified exploratory analysis to evaluate OS, PFS (by investigator assessment), and safety in the total study population (N = 612) at ~2 years from the last patient randomized7
  • 12.9% of patients in the placebo arm (26/202) crossed over to receive TUKYSA in combination with trastuzumab and capecitabine with the first patient crossover in February 20207
  • The median overall study follow-up: 29.6 months (data cutoff: February 8, 2021)7
  • Because formal testing of all alpha-controlled endpoints was considered final at the primary analysis, data from this prespecified updated analysis are for descriptive purposes only7

HER2CLIMB was the first randomized trial to study HER2+ MBC patients and active brain metastases1,8-13

PATIENTS WITH
VISCERAL METASTASES1,3*
74%
(455/612)
PATIENTS WITH BRAIN
METASTASES1†
48%
(291/612)

Of those patients who had brain metastases at baseline1:

  • 40% had stable brain metastases
  • 60% had active brain metastases

  23% had untreated progressing brain metastases

  - 37% had treated but progressing brain metastases

*Visceral disease was defined as tumors at all locations within the body except for those in the bone, brain, breast, chest wall, lymph nodes, neck, skin, and subcutaneous tissue. Tumors located in the pleura and peritoneum were classified as visceral disease.3

All patients received a brain MRI at baseline. Patients with brain metastases, including those with progressing or untreated lesions, were eligible provided they were neurologically stable and did not require immediate radiation or surgery. The trial excluded patients with leptomeningeal disease.1,2

MBC = metastatic breast cancer; MRI = magnetic resonance imaging.

Select Important Safety Information

Warnings and Precautions
  • Hepatotoxicity: TUKYSA can cause severe hepatotoxicity. Monitor ALT, AST, and bilirubin prior to starting TUKYSA, every 3 weeks during treatment, and as clinically indicated. Based on the severity of hepatotoxicity, interrupt dose, then dose reduce or permanently discontinue TUKYSA.
     
    In HER2CLIMB, 8% of patients who received TUKYSA had an ALT increase >5 × ULN, 6% had an AST increase >5 × ULN, and 1.5% had a bilirubin increase >3 × ULN (Grade ≥3). Hepatotoxicity led to TUKYSA dose reductions in 8% of patients and TUKYSA discontinuation in 1.5% of patients.

Please click here for Important Safety Information.

HER2CLIMB ASSESSED A BROAD POPULATION OF PATIENTS WITH HER2+ MBC2,3

                               
TUKYSA + trastuzumab +
capecitabine (n = 410)
Placebo + trastuzumab +
capecitabine (n =202)
Median age, years 55.0 54.0
Age <65 years, n (%) 328 (80.0) 168 (83.2)
Age ≥65 years, n (%) 82 (20.0) 34 (16.8)
PRIOR THERAPIES, n (%)
Trastuzumab 410 (100) 202 (100)
Pertuzumab 409 (99.8) 201 (99.5)
T-DM1 410 (100) 202 (100)
STAGE IV AT INITIAL DIAGNOSIS, n (%) 143 (34.9) 77 (38.1)
LOCATION OF METASTASES, n (%)
Visceral* 304 (74.1) 151 (74.8)
Bone 223 (54.4) 111 (55.0)
Brain 198 (48.3) 93 (46.0)
HORMONE RECEPTOR STATUS, n (%)
ER and/or PR positive 243 (59.3) 127 (62.9)
ER and PR negative 161 (39.3) 75 (37.1)
Other 6 (1.5) 0
ECOG PERFORMANCE STATUS, n (%)
0 204 (49.8) 94 (46.5)
1 206 (50.2) 108 (53.5)
RACE, n (%)
Asian 18 (4.4) 5 (2.5)
Black 41 (10.0) 14 (6.9)
White 287 (70.0) 157 (77.7)
Unknown/other 64 (15.6) 26 (12.9)
REGION OF WORLD, n (%)
United States and Canada 246 (60.0) 123 (60.9)
Rest of world 164 (40.0) 79 (39.1)

In HER2CLIMB, patients in the TUKYSA arm received a median of 3 prior lines of therapy in the metastatic setting (range: 1-14)1

*Visceral disease was defined as tumors at all locations within the body except for those in the bone, brain, breast, chest wall, lymph nodes, neck, skin, and subcutaneous tissue. Tumors located in the pleura and peritoneum were classified as visceral disease.3

Patients in the control arm received a median of 3 prior lines of therapy in the metastatic setting (range: 1-13).2

ER = estrogen receptor; PR = progesterone receptor.

Email icon

Keep current on news and updates.

Sign up here
Next: Explore survival data

Important Safety Information

Warnings and Precautions

  • Diarrhea: TUKYSA can cause severe diarrhea including dehydration, hypotension, acute kidney injury, and death. If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Perform diagnostic tests as clinically indicated to exclude other causes of diarrhea. Based on the severity of the diarrhea, interrupt dose, then dose reduce or permanently discontinue TUKYSA.

    In HER2CLIMB, when TUKYSA was given in combination with trastuzumab and capecitabine, 81% of patients who received TUKYSA experienced diarrhea, including 0.5% with Grade 4 and 12% with Grade 3. Both patients who developed Grade 4 diarrhea subsequently died, with diarrhea as a contributor to death. Median time to onset of the first episode of diarrhea was 12 days and the median time to resolution was 8 days. Diarrhea led to TUKYSA dose reductions in 6% of patients and TUKYSA discontinuation in 1% of patients. Prophylactic use of antidiarrheal treatment was not required on HER2CLIMB.

  • Hepatotoxicity: TUKYSA can cause severe hepatotoxicity. Monitor ALT, AST, and bilirubin prior to starting TUKYSA, every 3 weeks during treatment, and as clinically indicated. Based on the severity of hepatotoxicity, interrupt dose, then dose reduce or permanently discontinue TUKYSA.

    In HER2CLIMB, 8% of patients who received TUKYSA had an ALT increase >5 × ULN, 6% had an AST increase >5 × ULN, and 1.5% had a bilirubin increase >3 × ULN (Grade ≥3). Hepatotoxicity led to TUKYSA dose reductions in 8% of patients and TUKYSA discontinuation in 1.5% of patients.

  • Embryo-Fetal Toxicity: TUKYSA can cause fetal harm. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential, and male patients with female partners of reproductive potential, to use effective contraception during TUKYSA treatment and for 1 week after the last dose.

Adverse Reactions

In HER2CLIMB, serious adverse reactions occurred in 26% of patients who received TUKYSA; the most common (in ≥2% of patients) were diarrhea (4%), vomiting (2.5%), nausea (2%), abdominal pain (2%), and seizure (2%). Fatal adverse reactions occurred in 2% of patients who received TUKYSA including sudden death, sepsis, dehydration, and cardiogenic shock.

Adverse reactions led to treatment discontinuation in 6% of patients who received TUKYSA; the most common (in ≥1% of patients) were hepatotoxicity (1.5%) and diarrhea (1%). Adverse reactions led to dose reduction in 21% of patients who received TUKYSA; the most common (in ≥2% of patients) were hepatotoxicity (8%) and diarrhea (6%).

The most common adverse reactions in patients who received TUKYSA (≥20%) were diarrhea, palmar-plantar erythrodysesthesia, nausea, hepatotoxicity, vomiting, stomatitis, decreased appetite, anemia, and rash.

Lab Abnormalities

In HER2CLIMB, Grade ≥3 laboratory abnormalities reported in ≥5% of patients who received TUKYSA were decreased phosphate, increased ALT, decreased potassium, and increased AST.

The mean increase in serum creatinine was 32% within the first 21 days of treatment with TUKYSA. The serum creatinine increases persisted throughout treatment and were reversible upon treatment completion. Consider alternative markers of renal function if persistent elevations in serum creatinine are observed.

Drug Interactions

  • Strong CYP3A/Moderate CYP2C8 Inducers: Concomitant use may decrease TUKYSA activity. Avoid concomitant use of TUKYSA.
  • Strong or Moderate CYP2C8 Inhibitors: Concomitant use of TUKYSA with a strong CYP2C8 inhibitor may increase the risk of TUKYSA toxicity; avoid concomitant use. Increase monitoring for TUKYSA toxicity with moderate CYP2C8 inhibitors.
  • CYP3A Substrates: Concomitant use may increase the toxicity associated with a CYP3A substrate. Avoid concomitant use of TUKYSA where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage.
  • P-gp Substrates: Concomitant use may increase the toxicity associated with a P-gp substrate. Consider reducing the dosage of P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicity.

Use in Specific Populations

  • Lactation: Advise women not to breastfeed while taking TUKYSA and for 1 week after the last dose.
  • Renal Impairment: Use of TUKYSA in combination with capecitabine and trastuzumab is not recommended in patients with severe renal impairment (CLcr < 30 mL/min), because capecitabine is contraindicated in patients with severe renal impairment.
  • Hepatic Impairment: Reduce the dose of TUKYSA for patients with severe (Child-Pugh C) hepatic impairment.

REF-7648_FINAL_01/23

Indication

TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

Please see full Prescribing Information.

References
1. TUKYSA [Prescribing Information]. Bothell, WA: Seagen Inc. January 2023. 2. Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597-609. doi:10.1056/NEJMoa1914609 3. Data on file. Seagen Inc. 4. Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597-609. Supplementary appendix. doi:10.1056/NEJMoa1914609 5. Lin NU, Murthy RK, Abramson V, et al. Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol. Published online December 1, 2022. doi:10.1001/jamaoncol.2022.5610 6. Delgado A, Guddati AK. Clinical endpoints in oncology - a primer. Am J Cancer Res. 2021;11(4):1121-1131. 7. Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022;33(3):321-329. doi:10.1016/j.annonc.2021.12.005 8. Neratinib [Prescribing Information]. Los Angeles, CA: Puma Biotechnology, Inc. March 2022. 9. Fam-trastuzumab deruxtecan-nxki [Prescribing Information]. Basking Ridge, NJ: Daiichi Sankyo, Inc. August 2022. 10. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724-734. doi:10.1056/NEJMoa1413513 11. Rugo HS, Im SA, Cardoso F. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(4):573-584. 12. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-2743. doi:10.1056/NEJMoa064320  13. Krop IE, Lin NU, Blackwell K, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26(1):113-119. doi:10.1093/annonc/mdu486